Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

By B. Till, M. Jensen, Jinjuan Wang, E. Chen, B. Wood, H. Greisman, Xiaojun Qian, Scott E. James, A. Raubitschek, S. Forman and 6 more. Blood, 2008

727 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. (2011, background): “However, in the initial human trials, T lymphocytes expressing first-generation CARs showed limited expansion and relatively short persistence (3, 9, 10).”
Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. (2013, neutral): “Patients were treated with CAIX CAR T cells in three table 2 Patient characteristics and disease history before cAIX cAr t cell therapy cohort Patient number Age/sex nephrectomy (months from primary diagnosis till metastasis)a Prior treatmentb (months till progression) sites of evaluable diseasec 1 ”
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia (2013, neutral): “3),+11,del(14)(q2?q24),+16/46, XX[4].”